Teva announces Supreme Court denial of request for interim relief to stay court of appeals
Teva announced the U.S. denied Teva’s application to stay the Federal Circuit's decision due to the potential for the Company to recover patent infringement damages. The ‘808 patent expires Sept. 1, 2015 and claims a process for manufacturing the active ingredient of Teva’s RRMS product, COPAXONE®. April 19, 2014